We are a not-for-profit research group dedicated to CNS gene therapy translation acceleration. Our goal is to bring gene therapies for rare Central Nervous System diseases into clinical trials and use as quickly and efficiently as possible. Our first project is focused on developing a gene therapy for Huntington's disease. Future indications may include Tay Sachs and other lysosomal storage diseases affecting the central nervous system. As a not-for-profit corporation, we will be funded initially by foundations and government grants, and later by public donors. Any revenues we receive from successful therapies will be used to fund the development of therapies for additional rare CNS diseases, and maintain the availability of successful therapies.